Boehringer Ingelheim, Circle Pharma ink research collaboration to develop a novel precision cancer treatment: Ingelheim, Germany Friday, October 11, 2024, 12:00 Hrs [IST] Boehring ...
Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – is pleased to announce ...
Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in chronic pain management via Liposomal CBD drug products, today announced that it will be participating in ...
Adam Wandt, an attorney and deputy chair for technology at the John Jay School of Criminal Justice, said the barrage of state ...
In our experience working in the BI space over the past 15 years the Life Sciences sector and pharmaceutical manufacturers in particular have typically been ahead of the curve and fast to market ...
Purvi Tailor, Ferring Pharmaceuticals' VP of HR, says focusing holistically on worker well-being is crucial for retaining top ...
Boehringer Ingelheim and Circle Pharma have signed a partnership and licence agreement focused on developing a new cancer ...
As our digital focus continues, Daniel Ghinn explores the growing anticipation around Boehringer Ingelheim’s launch of Syrum – the first pharmaceutical social game – ahead of its beta launch ...
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the ...
INGELHEIM, Germany & SOUTH SAN FRANCISCO, Calif., October 09, 2024--Boehringer Ingelheim and Circle Pharma (Circle) announce a new research collaboration and license agreement with the shared goal to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback